MX344703B - Bloqueadores de canal de sodio poliaromaticos. - Google Patents

Bloqueadores de canal de sodio poliaromaticos.

Info

Publication number
MX344703B
MX344703B MX2010009099A MX2010009099A MX344703B MX 344703 B MX344703 B MX 344703B MX 2010009099 A MX2010009099 A MX 2010009099A MX 2010009099 A MX2010009099 A MX 2010009099A MX 344703 B MX344703 B MX 344703B
Authority
MX
Mexico
Prior art keywords
sodium channel
channel blockers
poly aromatic
aromatic sodium
poly
Prior art date
Application number
MX2010009099A
Other languages
English (en)
Other versions
MX2010009099A (es
Inventor
R Johnson Michael
Original Assignee
Parion Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parion Sciences Inc filed Critical Parion Sciences Inc
Publication of MX2010009099A publication Critical patent/MX2010009099A/es
Publication of MX344703B publication Critical patent/MX344703B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/30—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms in which said hetero-bound carbon atoms are part of a substructure —C(=X)—X—C(=X)—X— in which X is an oxygen or sulphur atom or an imino radical, e.g. imidoylguanidines
    • C07D241/32—(Amino-pyrazinoyl) guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan bloqueadores de canal de sodio poliaromáticos representados por la fórmula: (I), en donde las variables estructurales son como se definen en la presente invención. La presente invención también incluye una variedad de composiciones, combinaciones y métodos de tratamiento que utilizan estos bloqueadores de canal de sodio de la presente invención.
MX2010009099A 2008-02-26 2009-02-26 Bloqueadores de canal de sodio poliaromaticos. MX344703B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3146608P 2008-02-26 2008-02-26
PCT/US2009/035286 WO2009139948A1 (en) 2008-02-26 2009-02-26 Poly aromatic sodium channel blockers

Publications (2)

Publication Number Publication Date
MX2010009099A MX2010009099A (es) 2010-12-06
MX344703B true MX344703B (es) 2017-01-03

Family

ID=40998513

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009099A MX344703B (es) 2008-02-26 2009-02-26 Bloqueadores de canal de sodio poliaromaticos.

Country Status (14)

Country Link
US (3) US8124607B2 (es)
EP (1) EP2257296B1 (es)
JP (1) JP5611844B2 (es)
KR (1) KR101654549B1 (es)
CN (1) CN101951913A (es)
AR (1) AR070527A1 (es)
AU (1) AU2009246799B2 (es)
BR (1) BRPI0907823A2 (es)
CA (1) CA2713413C (es)
ES (1) ES2485642T3 (es)
MX (1) MX344703B (es)
NZ (1) NZ586940A (es)
TW (1) TWI432198B (es)
WO (1) WO2009139948A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
SI1663235T1 (sl) * 2003-08-18 2013-12-31 Parion Sciences, Inc. Zaščiteni pirazinoilgvanidinski blokatorji natrijevega kanala
US7807834B2 (en) * 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
ES2485642T3 (es) 2008-02-26 2014-08-14 Parion Sciences, Inc. Bloqueantes poli-aromáticos de los canales de sodio
US20100074881A1 (en) * 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems
AU2012267938B2 (en) 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2633177T3 (es) 2011-06-27 2017-09-19 Parion Sciences, Inc. Dipéptido química y metabólicamente estable que presenta una potente actividad bloqueadora de los canales de sodio
ES2675588T3 (es) 2012-05-29 2018-07-11 Parion Sciences, Inc. Dendrímero como aminoamidas que posee actividad de bloqueador de canal de sodio para el tratamiento del ojo seco y otras enfermedades mucosas
ES2674665T3 (es) * 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CN105073717B (zh) * 2012-12-17 2018-05-22 帕里昂科学公司 可用于治疗由黏膜水化不足造成的疾病的氯-吡嗪甲酰胺衍生物
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
CN103408503B (zh) * 2013-08-21 2015-03-11 中国科学院南海海洋研究所 一种生物碱类化合物的制备方法及其在制备抑制钙离子通道药物中的应用
SG11201601291QA (en) 2013-08-23 2016-03-30 Parion Sciences Inc Dithiol mucolytic agents
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015128402A1 (en) * 2014-02-28 2015-09-03 Rhodia Operations Process for the preparation of precipitated silicas, precipitated silicas and their uses, in particular for the reinforcement of polymers
US20150376145A1 (en) 2014-06-30 2015-12-31 Parion Sciences, Inc. Stable sodium channel blockers
CN107614480B (zh) 2015-01-30 2020-09-15 帕里昂科学公司 新型单硫醇粘液溶解剂
WO2016176423A1 (en) 2015-04-30 2016-11-03 Parion Sciences, Inc. Novel prodrugs of dithiol mucolytic agents
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
WO2023146892A1 (en) * 2022-01-26 2023-08-03 Parion Sciences, Inc. Biphenyl-substituted epithelial sodium channel blocking compounds
WO2023146896A1 (en) * 2022-01-26 2023-08-03 Parion Sciences, Inc. Bicyclic-substituted epithelial sodium channel blocking compounds

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639386A (es) * 1962-10-30
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4479932A (en) 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS6032714A (ja) 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
US4894376A (en) * 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5182299A (en) 1990-03-19 1993-01-26 Brigham And Women's Hospital Treatment of osmotic disturbance with organic osmolytes
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
EP1693080A3 (en) 1991-07-02 2007-07-25 Nektar Therapeutics Method and device for delivering aeroslized medicaments
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
WO1994008552A2 (en) 1992-10-19 1994-04-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
US5819726A (en) 1993-01-29 1998-10-13 Aradigm Corporation Method for the delivery of aerosolized drugs to the lung for the treatment of respiratory disease
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5645051A (en) 1995-04-21 1997-07-08 Dura Pharmaceuticals, Inc. Unit dose dry powder inhaler
US5622166A (en) 1995-04-24 1997-04-22 Dura Pharmaceuticals, Inc. Dry powder inhaler delivery system
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
DE69934435T2 (de) 1998-10-20 2007-09-27 University Of North Carolina At Chapel Hill Methoden zum befeuchten der nasenschleimhaut
US20040195160A1 (en) * 1999-07-12 2004-10-07 Marine Desalination Systems, L.L.C. Hydrate-based reduction of fluid inventories and concentration of aqueous and other water-containing products
US20040199456A1 (en) * 2000-08-01 2004-10-07 Andrew Flint Method and apparatus for explaining credit scores
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US20050227974A9 (en) * 2002-08-01 2005-10-13 Euro-Celtique S.A. Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
SI1663235T1 (sl) 2003-08-18 2013-12-31 Parion Sciences, Inc. Zaščiteni pirazinoilgvanidinski blokatorji natrijevega kanala
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US7375107B2 (en) * 2003-08-18 2008-05-20 Parion Sciences, Inc. Alaphatic pyrazinoylguanidine sodium channel blockers
JP2007502829A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 環状ピラジノイルグアニジンナトリウムチャネルブロッカー
US20090253714A1 (en) 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7956059B2 (en) 2004-08-18 2011-06-07 Parion Sciences, Inc. Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers
US20090324724A1 (en) 2004-08-18 2009-12-31 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
WO2006023617A2 (en) * 2004-08-18 2006-03-02 Johnson Michael R Cyclic amide & ester pyrazinoylguanidine sodium channel blockers
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526240D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2653757A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
WO2007146870A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
CA2654244A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
CA2663041A1 (en) * 2006-09-07 2008-03-13 Parion Sciences, Inc. Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US7981898B2 (en) * 2006-09-07 2011-07-19 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
US8288391B2 (en) * 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
WO2008124496A1 (en) * 2007-04-03 2008-10-16 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough, and central nervous system disorders
ES2361595T3 (es) 2007-05-07 2011-06-20 Novartis Ag Compuestos orgánicos.
EP2211956A4 (en) 2007-10-10 2014-07-09 Parion Sciences Inc DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
ES2485642T3 (es) 2008-02-26 2014-08-14 Parion Sciences, Inc. Bloqueantes poli-aromáticos de los canales de sodio
KR20110011621A (ko) 2008-05-13 2011-02-08 노파르티스 아게 ３，５―디아미노―６―클로로―피라진―２―카르복실산 유도체 및 기도 질환의 치료를 위한 상피 나트륨 채널 차단제로서의 이들의 용도
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US20100074881A1 (en) 2008-07-11 2010-03-25 Parion Sciences, Inc. Multiple nebulizer systems

Also Published As

Publication number Publication date
EP2257296A1 (en) 2010-12-08
CA2713413C (en) 2018-11-20
WO2009139948A1 (en) 2009-11-19
AU2009246799A1 (en) 2009-11-19
AR070527A1 (es) 2010-04-14
CA2713413A1 (en) 2009-11-19
JP5611844B2 (ja) 2014-10-22
EP2257296B1 (en) 2014-05-07
US8124607B2 (en) 2012-02-28
US20120116083A1 (en) 2012-05-10
US20140031371A1 (en) 2014-01-30
ES2485642T3 (es) 2014-08-14
MX2010009099A (es) 2010-12-06
KR101654549B1 (ko) 2016-09-07
BRPI0907823A2 (pt) 2015-07-21
US8575176B2 (en) 2013-11-05
US20090214444A1 (en) 2009-08-27
TW200940059A (en) 2009-10-01
CN101951913A (zh) 2011-01-19
NZ586940A (en) 2012-08-31
TWI432198B (zh) 2014-04-01
KR20100119878A (ko) 2010-11-11
JP2011513325A (ja) 2011-04-28
EP2257296A4 (en) 2011-04-20
AU2009246799B2 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
MX344703B (es) Bloqueadores de canal de sodio poliaromaticos.
PH12014502624B1 (en) Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
GEP20135898B (en) Rifaximin forms and usage
MY153915A (en) Organic compounds
MX2011013762A (es) Polimeros de tinte anionico.
UA107791C2 (en) Pesticidal compositions
IN2015DN00960A (es)
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
MX2007006178A (es) Fenoles substituidos como agentes activos que inhiben la produccion del factor de crecimiento endotelial vascular.
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
UA104438C2 (uk) Спосіб одержання дабігатрану і його проміжних сполук
MX2012008141A (es) Compuestos y metodos.
WO2011005594A3 (en) Antimicrobial compositions and methods of making and using the same
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
GEP20135788B (en) Octenidine composition
MX2010004487A (es) Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
MX2009007336A (es) Indazoles substituidos con 5-furopiridinona.
IN2015DN01230A (en) Pyrrolopyrazoles as n type calcium channel blockers
MX2009009490A (es) Profarmacos novedosos.
HK1124842A1 (en) Methods of preparing imidazole-based compounds
TN2009000536A1 (en) Novel herbicides
TN2011000355A1 (en) Novel microbiocides

Legal Events

Date Code Title Description
FG Grant or registration